Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Anne KniselyJibran AhmedBettzy StephenSarina A Piha-PaulDaniel KarpAbdulrazzak ZarifaSiqing FuDavid Sanghyun HongJordi Rodon AhnertTimothy A YapApostolia-Maria TsimberidouAnas AlshawaEcaterina E DumbravaYali YangJuhee SongFunda Meric-BernstamAmir A JazaeriAung NaingPublished in: Cancer (2023)
The findings from this trial highlight that, in heavily pretreated patients with gynecologic cancer, even multidrug regimens targeting multiple immunologic pathways, although safe, did not produce significant responses. A DCR of 78% in patients with cervical cancer who received avelumab and utomilumab indicates that further research on this combination in select patients may be warranted.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical trial
- papillary thyroid
- prognostic factors
- endometrial cancer
- radiation therapy
- peritoneal dialysis
- randomized controlled trial
- growth factor
- squamous cell carcinoma
- radiation induced
- cancer therapy
- phase ii
- patient reported outcomes
- lymph node metastasis
- open label